What is Atossa Therapeutics Inc's earnings per share (EPS)?

Atossa Therapeutics Inc (ATOS) reported diluted earnings per share of $-4.04 for fiscal year 2025. EPS represents the portion of a company's net income allocated to each outstanding share of common stock and is widely used to evaluate profitability on a per-share basis.

Atossa Therapeutics Inc Financials

ATOS

Source SEC Filings (10-K/10-Q) Updated Mar 25, 2026 Currency USD FYE March

This page shows Atossa Therapeutics Inc (ATOS) financial statements, including the income statement, balance sheet, cash flow statement, and key financial ratios. View 16 years of annual fundamentals and quarterly data, with year-over-year growth rates and compound annual growth rates (CAGR). All figures are derived from SEC filings (10-K and 10-Q reports).

Financial Health Signals

Piotroski F-Score Weak

2/9

Atossa Therapeutics Inc passes 2 of 9 financial strength tests. 1 of 4 profitability signals pass, 1 of 3 leverage/liquidity signals pass.

Earnings Quality Low Quality

0.86x

For every $1 of reported earnings, Atossa Therapeutics Inc generates $0.86 in operating cash flow (-$29.8M OCF vs -$34.8M net income). This low ratio suggests earnings are primarily driven by accounting accruals rather than cash generation, which may not be sustainable.

Key Financial Metrics

Export CSV

Earnings & Revenue

Revenue

N/A

EBITDA

-$37.1M

YoY-34.5%

Atossa Therapeutics Inc's EBITDA was -$37.1M in fiscal year 2025, measuring earnings before interest, taxes, depreciation, and amortization. This represents a decrease of 34.5% from the prior year.

Net Income

-$34.8M

YoY-36.3%

Atossa Therapeutics Inc reported -$34.8M in net income in fiscal year 2025. This represents a decrease of 36.3% from the prior year.

EPS (Diluted)

$-4.04

Atossa Therapeutics Inc earned $-4.04 per diluted share (EPS) in fiscal year 2025. This represents a decrease of 1920.0% from the prior year.

Cash & Balance Sheet

Free Cash Flow

-$29.8M

YoY-41.5%

Atossa Therapeutics Inc generated -$29.8M in free cash flow in fiscal year 2025, representing cash available after capex. This represents a decrease of 41.5% from the prior year.

Cash & Debt

$41.3M

YoY-41.9%

5Y CAGR+0.9%

10Y CAGR+27.2%

Atossa Therapeutics Inc held $41.3M in cash against $0 in long-term debt as of fiscal year 2025.

Dividends Per Share

N/A

Shares Outstanding

Atossa Therapeutics Inc had 9M shares outstanding in fiscal year 2025. This represents a decrease of 93.3% from the prior year.

Margins & Returns

Gross Margin

N/A

Operating Margin

N/A

Net Margin

N/A

Return on Equity

-88.3%

YoY-52.7pp

5Y CAGR-22.7pp

10Y CAGR+332.9pp

Atossa Therapeutics Inc's ROE was -88.3% in fiscal year 2025, measuring profit generated per dollar of shareholder equity. This is down 52.7 percentage points from the prior year.

Capital Allocation

R&D Spending

$21.2M

YoY+50.1%

5Y CAGR+26.2%

10Y CAGR+24.5%

Atossa Therapeutics Inc invested $21.2M in research and development in fiscal year 2025. This represents an increase of 50.1% from the prior year.

Share Buybacks

N/A

Capital Expenditures

$23K

YoY+21.1%

5Y CAGR+20.6%

Atossa Therapeutics Inc invested $23K in capex in fiscal year 2025, funding long-term assets and infrastructure. This represents an increase of 21.1% from the prior year.

ATOS Income Statement

Metric	FY25	FY24	FY23	FY22	FY21	FY20
Revenue	N/A	N/A	N/A	N/A	N/A	N/A
Cost of Revenue	N/A	N/A	N/A	N/A	N/A	N/A
Gross Profit	N/A	N/A	N/A	N/A	N/A	N/A
R&D Expenses	$21.2M+50.1%	$14.1M-18.6%	$17.3M+14.9%	$15.1M+63.8%	$9.2M+39.4%	$6.6M
SG&A Expenses	$16.0M+18.2%	$13.5M-3.8%	$14.0M+11.4%	$12.6M+11.5%	$11.3M+41.4%	$8.0M
Operating Income	-$37.1M-34.5%	-$27.6M+12.0%	-$31.4M-13.3%	-$27.7M-34.9%	-$20.5M-40.5%	-$14.6M
Interest Expense	N/A	N/A	N/A	N/A	N/A	N/A
Income Tax	N/A	$0	$0	$0	$0	$0
Net Income	-$34.8M-36.3%	-$25.5M+15.3%	-$30.1M-11.6%	-$27.0M-30.8%	-$20.6M-15.6%	-$17.8M
EPS (Diluted)	$-4.04	$-0.20+16.7%	$-0.24-14.3%	$-0.21	N/A	N/A

Metric	Q2'26	Q1'26	Q4'25	Q3'25	Q2'25	Q1'25	Q4'24	Q3'24
Revenue	N/A	N/A	N/A	N/A	N/A	N/A	N/A	N/A
Cost of Revenue	N/A	N/A	N/A	N/A	N/A	N/A	N/A	N/A
Gross Profit	N/A	N/A	N/A	N/A	N/A	N/A	N/A	N/A
R&D Expenses	$5.4M-2.4%	$5.5M+32.4%	$4.2M	N/A	$3.4M-4.0%	$3.6M-5.2%	$3.7M	N/A
SG&A Expenses	$3.9M+9.7%	$3.5M+8.6%	$3.3M	N/A	$3.0M-16.3%	$3.6M+9.9%	$3.2M	N/A
Operating Income	-$9.3M-2.3%	-$9.0M-21.9%	-$7.4M	N/A	-$6.4M+10.1%	-$7.1M-1.8%	-$7.0M	N/A
Interest Expense	N/A	N/A	N/A	N/A	N/A	N/A	N/A	N/A
Income Tax	$0	$0	$0	N/A	$0	$0	$0	N/A
Net Income	-$8.7M-3.2%	-$8.4M-25.4%	-$6.7M	N/A	-$7.2M-19.5%	-$6.0M-2.9%	-$5.9M	N/A
EPS (Diluted)	$-0.070.0%	$-0.07-40.0%	$-0.05	N/A	$-0.06-20.0%	$-0.050.0%	$-0.05	N/A

ATOS Balance Sheet

Metric	FY25	FY24	FY23	FY22	FY21	FY20
Total Assets	$47.6M-37.7%	$76.4M-20.6%	$96.3M-22.1%	$123.5M-12.6%	$141.3M+229.8%	$42.8M
Current Assets	$45.6M-38.7%	$74.5M-19.3%	$92.2M-22.0%	$118.2M-16.3%	$141.2M+230.2%	$42.8M
Cash & Equivalents	$41.3M-41.9%	$71.1M-19.6%	$88.5M-20.2%	$110.9M-18.7%	$136.4M+244.8%	$39.6M
Inventory	N/A	N/A	N/A	N/A	N/A	N/A
Accounts Receivable	N/A	N/A	N/A	N/A	N/A	N/A
Goodwill	N/A	N/A	N/A	N/A	N/A	N/A
Total Liabilities	$8.3M+66.2%	$5.0M-5.1%	$5.2M-6.0%	$5.6M+78.1%	$3.1M-80.1%	$15.7M
Current Liabilities	$8.3M+66.2%	$5.0M-5.1%	$5.2M-6.0%	$5.6M+78.1%	$3.1M-80.1%	$15.7M
Long-Term Debt	N/A	N/A	N/A	N/A	N/A	N/A
Total Equity	$39.4M-44.9%	$71.5M-21.5%	$91.0M-22.8%	$118.0M-14.6%	$138.1M+408.5%	$27.2M
Retained Earnings	-$246.6M-16.4%	-$211.8M-13.7%	-$186.3M-19.3%	-$156.2M-20.9%	-$129.2M-15.5%	-$111.9M

Metric	Q2'26	Q1'26	Q4'25	Q3'25	Q2'25	Q1'25	Q4'24	Q3'24
Total Assets	$58.0M-10.1%	$64.5M-8.8%	$70.7M-7.5%	$76.4M-3.8%	$79.5M-7.4%	$85.9M-5.7%	$91.1M-5.4%	$96.3M
Current Assets	$55.7M-10.9%	$62.5M-9.1%	$68.7M-7.7%	$74.5M-3.4%	$77.1M-5.6%	$81.7M-6.1%	$87.1M-5.6%	$92.2M
Cash & Equivalents	$51.8M-10.4%	$57.9M-11.1%	$65.1M-8.4%	$71.1M-4.9%	$74.8M-6.0%	$79.5M-5.3%	$84.0M-5.1%	$88.5M
Inventory	N/A	N/A	N/A	N/A	N/A	N/A	N/A	N/A
Accounts Receivable	N/A	N/A	N/A	N/A	N/A	N/A	N/A	N/A
Goodwill	N/A	N/A	N/A	N/A	N/A	N/A	N/A	N/A
Total Liabilities	$8.2M+20.6%	$6.8M+25.7%	$5.4M+9.2%	$5.0M-14.3%	$5.8M+1.8%	$5.7M+6.9%	$5.3M+1.8%	$5.2M
Current Liabilities	$8.2M+20.6%	$6.8M+25.7%	$5.4M+9.2%	$5.0M-14.3%	$5.8M+1.8%	$5.7M+6.9%	$5.3M+1.8%	$5.2M
Long-Term Debt	N/A	N/A	N/A	N/A	N/A	N/A	N/A	N/A
Total Equity	$49.8M-13.7%	$57.7M-11.7%	$65.3M-8.6%	$71.5M-3.0%	$73.7M-8.1%	$80.2M-6.5%	$85.8M-5.8%	$91.0M
Retained Earnings	-$235.6M-3.8%	-$226.9M-3.9%	-$218.5M-3.2%	-$211.8M-3.1%	-$205.4M-3.6%	-$198.2M-3.1%	-$192.2M-3.2%	-$186.3M

ATOS Cash Flow Statement

Metric	FY25	FY24	FY23	FY22	FY21	FY20
Operating Cash Flow	-$29.8M-41.5%	-$21.0M-0.4%	-$20.9M-0.9%	-$20.8M-26.0%	-$16.5M-42.4%	-$11.6M
Capital Expenditures	$23K+21.1%	$19K+35.7%	$14K-48.1%	$27K+200.0%	$9K0.0%	$9K
Free Cash Flow	-$29.8M-41.5%	-$21.0M-0.4%	-$21.0M-0.8%	-$20.8M-26.1%	-$16.5M-42.3%	-$11.6M
Investing Cash Flow	-$23K-21.1%	-$19K-35.7%	-$14K+99.7%	-$4.7M-52422.2%	-$9K0.0%	-$9K
Financing Cash Flow	$3.7M0.0%	$3.7M+349.0%	-$1.5M	$0-100.0%	$113.3M+193.9%	$38.6M
Dividends Paid	N/A	N/A	N/A	N/A	N/A	N/A
Share Buybacks	N/A	$0-100.0%	$1.5M	$0	N/A	N/A

Metric	Q2'26	Q1'26	Q4'25	Q3'25	Q2'25	Q1'25	Q4'24	Q3'24
Operating Cash Flow	-$6.0M+17.3%	-$7.3M-21.8%	-$6.0M+15.5%	-$7.1M-48.4%	-$4.8M-4.8%	-$4.5M+3.6%	-$4.7M+15.7%	-$5.6M
Capital Expenditures	$7K	$0-100.0%	$9K	$0-100.0%	$10K+233.3%	$3K-50.0%	$6K	$0
Free Cash Flow	-$6.0M+17.2%	-$7.3M-21.6%	-$6.0M+15.4%	-$7.1M-48.1%	-$4.8M-5.0%	-$4.5M+3.6%	-$4.7M+15.6%	-$5.6M
Investing Cash Flow	-$7K	$0+100.0%	-$9K	$0+100.0%	-$10K-233.3%	-$3K+50.0%	-$6K	$0
Financing Cash Flow	$0	$0	$0-100.0%	$3.4M	$0-100.0%	$100K-51.0%	$204K	$0
Dividends Paid	N/A	N/A	N/A	N/A	N/A	N/A	N/A	N/A
Share Buybacks	N/A	N/A	N/A	N/A	N/A	N/A	N/A	$0

ATOS Financial Ratios

Metric	FY25	FY24	FY23	FY22	FY21	FY20
Gross Margin	N/A	N/A	N/A	N/A	N/A	N/A
Operating Margin	N/A	N/A	N/A	N/A	N/A	N/A
Net Margin	N/A	N/A	N/A	N/A	N/A	N/A
Return on Equity	-88.3%-52.7pp	-35.7%-2.6pp	-33.1%-10.2pp	-22.9%-7.9pp	-14.9%+50.7pp	-65.6%
Return on Assets	-73.0%-39.7pp	-33.4%-2.1pp	-31.3%-9.4pp	-21.8%-7.2pp	-14.6%+27.0pp	-41.6%
Current Ratio	5.53-9.5	14.99-2.6	17.61-3.6	21.23-24.0	45.18+42.5	2.73
Debt-to-Equity	0.21+0.1	0.07+0.0	0.06+0.0	0.05+0.0	0.02-0.6	0.58
FCF Margin	N/A	N/A	N/A	N/A	N/A	N/A

Metric	Q2'26	Q1'26	Q4'25	Q3'25	Q2'25	Q1'25	Q4'24	Q3'24
Gross Margin	N/A	N/A	N/A	N/A	N/A	N/A	N/A	N/A
Operating Margin	N/A	N/A	N/A	N/A	N/A	N/A	N/A	N/A
Net Margin	N/A	N/A	N/A	N/A	N/A	N/A	N/A	N/A
Return on Equity	-17.5%-2.9pp	-14.6%-4.3pp	-10.3%	N/A	-9.8%-2.3pp	-7.5%-0.7pp	-6.9%	N/A
Return on Assets	-15.0%-1.9pp	-13.1%-3.6pp	-9.5%	N/A	-9.1%-2.1pp	-7.0%-0.6pp	-6.5%	N/A
Current Ratio	6.77-2.4	9.17-3.5	12.67-2.3	14.99+1.7	13.30-1.0	14.35-2.0	16.34-1.3	17.61
Debt-to-Equity	0.17+0.0	0.12+0.0	0.08+0.0	0.070.0	0.080.0	0.070.0	0.060.0	0.06
FCF Margin	N/A	N/A	N/A	N/A	N/A	N/A	N/A	N/A

Similar Companies

Pyxis Oncology, Inc. PYXS

$91.7M

Adagene Inc. ADAG

$184.8M

Spero Therapeuti SPRO

$135.5M

Alto Neuroscienc ANRO

$718.1M

Macrogenics Inc MGNX

$183.7M

Frequently Asked Questions

Is Atossa Therapeutics Inc profitable?

No, Atossa Therapeutics Inc (ATOS) reported a net income of -$34.8M in fiscal year 2025.

What is Atossa Therapeutics Inc's EBITDA?

Atossa Therapeutics Inc (ATOS) had EBITDA of -$37.1M in fiscal year 2025, measuring earnings before interest, taxes, depreciation, and amortization.

What is Atossa Therapeutics Inc's return on equity (ROE)?

Atossa Therapeutics Inc (ATOS) has a return on equity of -88.3% for fiscal year 2025, measuring how efficiently the company generates profit from shareholder equity.

What is Atossa Therapeutics Inc's free cash flow?

Atossa Therapeutics Inc (ATOS) generated -$29.8M in free cash flow during fiscal year 2025. This represents a -41.5% change compared to the previous fiscal year. Free cash flow represents the cash a company generates after accounting for capital expenditures, and is widely used to assess financial flexibility and shareholder value.

What is Atossa Therapeutics Inc's operating cash flow?

Atossa Therapeutics Inc (ATOS) generated -$29.8M in operating cash flow during fiscal year 2025, representing cash generated from core business activities.

What are Atossa Therapeutics Inc's total assets?

Atossa Therapeutics Inc (ATOS) had $47.6M in total assets as of fiscal year 2025, including both current and long-term assets.

What are Atossa Therapeutics Inc's capital expenditures?

Atossa Therapeutics Inc (ATOS) invested $23K in capital expenditures during fiscal year 2025, funding long-term assets and infrastructure.

How much does Atossa Therapeutics Inc spend on research and development?

Atossa Therapeutics Inc (ATOS) invested $21.2M in research and development during fiscal year 2025.

How many shares does Atossa Therapeutics Inc have outstanding?

Atossa Therapeutics Inc (ATOS) had 9M shares outstanding as of fiscal year 2025.

What is Atossa Therapeutics Inc's current ratio?

Atossa Therapeutics Inc (ATOS) had a current ratio of 5.53 as of fiscal year 2025, which is generally considered healthy.

What is Atossa Therapeutics Inc's debt-to-equity ratio?

Atossa Therapeutics Inc (ATOS) had a debt-to-equity ratio of 0.21 as of fiscal year 2025, measuring the company's financial leverage by comparing total debt to shareholder equity.

What is Atossa Therapeutics Inc's return on assets (ROA)?

Atossa Therapeutics Inc (ATOS) had a return on assets of -73.0% for fiscal year 2025, measuring how efficiently the company uses its assets to generate profit.

What is Atossa Therapeutics Inc's cash runway?

Based on fiscal year 2025 data, Atossa Therapeutics Inc (ATOS) had $41.3M in cash against an annual operating cash burn of $29.8M. This gives an estimated cash runway of approximately 17 months at the current burn rate. Cash runway measures how long a company can continue operating before running out of cash, assuming no additional funding.

What is Atossa Therapeutics Inc's Piotroski F-Score?

Atossa Therapeutics Inc (ATOS) has a Piotroski F-Score of 2 out of 9, indicating weak financial health. The F-Score evaluates nine binary signals across profitability (positive ROA, positive cash flow, improving ROA, earnings quality), leverage (decreasing debt, improving liquidity, no share dilution), and operating efficiency (improving gross margin, improving asset turnover). Scores of 7–9 indicate strong and improving fundamentals. Learn more in our complete guide to financial health indicators.

Are Atossa Therapeutics Inc's earnings high quality?

Atossa Therapeutics Inc (ATOS) has an earnings quality ratio of 0.86x, considered low quality (accrual-driven). This ratio compares operating cash flow to net income. A ratio above 1.0x means the company generates more cash than its reported earnings, indicating sustainable, cash-backed profits. Ratios below 1.0x suggest earnings rely on accounting accruals rather than actual cash generation. Learn more in our complete guide to financial health indicators.